cover image - Heart Failure, 5th Edition
ISBN: 9780443119866
Copyright: 2028
Page Count: 624
Imprint: Elsevier
List Price: $199.99

Heart Failure, 5th Edition

by Douglas L. Mann, MD, G. Michael Felker, MD, MHS, FACC, FAHA and Scott D. Solomon

Hardcover

cover image - Heart Failure, 5th Edition
ISBN: 9780443119866
Copyright: 2028
Page Count: 624
Imprint: Elsevier
List Price: $199.99

$199.99

Free Shipping!
Not Yet Available
Coming Soon!
Expected availability date: 02-12-2027
Part of the renowned Braunwald family of references, Heart Failure, 5th Edition, provides the clinically relevant information you need to effectively manage and treat patients with this complex cardiovascular problem. This fully revised companion to Braunwald’s Heart Disease helps you make the most of new drug therapies, recently improved implantable devices, and innovative patient management strategies. Led by internationally recognized heart failure experts Drs. Douglas L. Mann, G. Michael Felker, and Scott D. Solomon, this award-winning reference is up to date, authoritative, and comprehensive—an essential resource for improving clinical outcomes in heart failure patients.
    • Focuses on a clinical approach to treating heart failure resulting from a broad variety of cardiovascular problems
    • Covers key topics such as new drug therapies for HFrEF and HFpEF, novel devices, precision medicine, and HF prevention
    • Reflects the most recent guidelines and protocols, including new updates to ACC, AHA, and HFSA guidelines
    • Discusses the pathophysiological basis for the development and progression of heart failure
    • Serves as a definitive resource to prepare for the ABIM’s Heart Failure board exam
    • An eBook version is included with purchase. The eBook allows you to access all of the text, figures, and references, with the ability to search, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish after the publication date

  • Section I: Basic Mechanisms of Heart Failure and Disease Progression

    1. Molecular and Cellular Basis for Heart Failure
    2. Molecular Signaling Mechanisms of the Renin-Angiotensin System in Heart Failure
    3. Adrenergic Receptor Signaling in Heart Failure
    4. Role of Innate Immune Activation in Heart Failure
    5. Natriuretic Peptides in Heart Failure
    6. Alterations in Systolic and Diastolic Ventricular Function in Heart Failure
    7. Alterations in Ventricular Structure: Role of Adverse Left Ventricular Remodeling and Reverse Remodeling in Heart Failure
    8. Alterations in the Sympathetic and Parasympathetic Nervous Systems in Heart Failure
    9. Alterations in the Peripheral Circulation in Heart Failure
    10. Alterations in Kidney Function Associated With Heart Failure
    11. Alterations in Skeletal Muscle in Heart Failure
    12. Alterations in Cardiac Metabolism in Heart Failure
    13. Mechanisms of Congestion in Heart Failure

    Section II: Etiological Basis for Heart Failure
    14. Epidemiology of Heart Failure
    15. Heart Failure as a Consequence of Ischemic Heart Disease
    16. Heart Failure as a Consequence of Dilated Cardiomyopathy
    17. Restrictive Cardiomyopathies and Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
    18. Amyloidosis as a Cause of Heart Failure
    19. Heart Failure as a Consequence of Hypertrophic Cardiomyopathy
    20. Heart Failure as a Consequence of Genetic Cardiomyopathy
    21. Heart Failure as a Consequence of Valvular Heart Disease
    22. Heart Failure as a Consequence of Congenital Heart Disease
    23. Heart Failure as a Consequence of Viral and Nonviral Myocarditis
    24. Heart Failure in Low- and Middle-Income Country Contexts
    25. Heart Failure and Human Immunodeficiency Virus
    26. Coronavirus Disease 2019 and Heart Failure

    Section III: Clinical Assessment of Heart Failure
    27. Clinical Evaluation of Heart Failure
    28. Advanced Cardiac Imaging in Heart Failure: A Disease-Based Approach
    29. Biomarkers in Precision Medicine
    30. Hemodynamics in Heart Failure

    Section IV: Therapy for Heart Failure
    31. Disease Prevention in Heart Failure
    32. Modulators of the Renin-Angiotensin-Aldosterone System and the Vasoactive Peptide System in Heart Failure
    33. Beta-Adrenergic Blockers
    34. Sodium-Glucose Cotransporter Inhibitors in Heart Failure
    35. Acute Heart Failure
    36. Additional Medical Therapies for Heart Failure Patients With Reduced Ejection Fraction
    37. Management of Arrhythmias and Cardiac Implantable Electronic Devices in Heart Failure
    38. Treatment of Heart Failure With Mildly Reduced or Preserved Ejection Fraction
    39. Management of Heart Failure in Special Populations: Older Patients, Females, and Racial or Ethnic Minority Groups
    40. Gene Therapy in Heart Failure
    41. Neuromodulation in Heart Failure
    42. Pulmonary Hypertension and the Right Ventricle
    43. Heart Transplantation
    44. Circulatory Assist Devices in Heart Failure
    45. Cardio-Oncology and Heart Failure
    46. Telemedicine in Heart Failure
    47. Management of Comorbidities in Heart Failure
    48. Implementation Science in Heart Failure
    49. Decision-Making and Palliative Care in Advanced Heart Failure

  • Douglas L. Mann, MD, Ada L. Steininger Professor of Cardiology and Professor of Medicine, Cell Biology, and Physiology, Washington University School of Medicine in St. Louis, Cardiologist-in-Chief, Barnes-Jewish Hospital, St. Louis, Missouri, USA, G. Michael Felker, MD, MHS, FACC, FAHA, Professor of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina and Scott D. Solomon, Edward D. Frohlich Endowed Chair, Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital/ Mass General Brigham, Boston, Massachusetts
  • No accessibility information is available for this product.

$199.99

Free Shipping!
Not Yet Available
Coming Soon!
Expected availability date: 02-12-2027